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Abstract
Background
Obesity is a leading comorbidity in psoriatic disease, including both psoriasis (PsO) and pso-
riatic arthritis (PsA), and is associated with adverse metabolic and cardiovascular (CV) out-
comes. Anthropometric parameters, such as weight, body mass index (BMI) and waist-to-
hip ratio, have been extensively reported in psoriatic disease. However, the associations of
body composition and fat distribution with psoriasis have not yet been fully defined.
Objectives
To identify whether patients with psoriatic disease, including psoriatic arthritis, have altered
body composition compared with the general population, and to review existing modalities
for the assessment of body composition.
Methods
Electronic searches of the literature were conducted in PubMed, Medline (Ovid®), Embase
(Ovid®), Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar.
Titles and abstracts were reviewed by two authors independently against a set of prespeci-
fied inclusion/exclusion criteria. The research question was answered with a systematic lit-
erature review and results were summarized narratively.
Results
Twenty-five full text articles met the inclusion criteria and were included in the final narrative
analysis. The studies were of heterogeneous design and used a range of objective mea-
sures to assess body composition, including simple anthropometric measures, bioimpe-
dance analysis (BIA), dual energy X-ray absorptiometry (DXA) and computed tomography
(CT). Few studies met all the quality assessment criteria. Clinical heterogeneity prevented
meta-analysis.
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Conclusions
Patients with psoriatic disease reveal defined body composition changes that are indepen-
dent of obesity and the customary metabolic syndrome, including higher overall body fat,
visceral fat and sarcopenia. These findings emphasize that patients with psoriatic disease
should be screened for abnormal adipose effects beyond their weight and body mass index
(BMI). Our findings show that the last decade has seen an exciting expansion of research
interest in the development and validation of new modalities for the assessment of body
composition. There is no consensus on the optimal assessment method of body composi-
tion for this diverse group; hence there is a need for validation of existing modalities and
standardization of assessment tools.
Introduction
Psoriasis (PsO) is an immune-mediated chronic inflammatory disease affecting the skin,
entheses and joints, with an estimated prevalence in adults ranging from 0.5 to 11.4% and in
children from 0 to 1.4% [1]. It is characterized at the skin level by infiltration of immune cells
in the dermis and epidermis, vascular proliferation and atypical keratinocyte differentiation.
Pathogenesis is complex and thought to result from the interaction between genetic, environ-
mental and immunologic factors; key players in this process are T cells, antigen presenting
cells, keratinocytes, Langerhans’ cells, macrophages, natural killer cells, as well as multiple
cytokines and growth factors including vascular endothelial growth factor and keratinocyte
growth factor [2]. In recent years, the mindset has shifted from one of a Th1-driven immune
response with IFN-γ and IL-12 as the signature cytokines to one in which the IL-23/Th17 axis
with IL-17, IL-21 and IL-22 plays a more central role [3]. Fig 1 illustrates the immunopatho-
genesis of psoriasis.
There is increasing recognition that psoriasis is more than skin deep and has important
consequences beyond the skin. Proinflammatory molecules released during chronic inflamma-
tion are implicated in certain co-morbidities, such as obesity, hypertension, diabetes mellitus,
cardiovascular disease and depression. Paradoxically, epidemiologic evidence infers that obe-
sity, via pro-inflammatory pathways, predisposes to both development and progression of pso-
riasis [4]. This association is shared with metabolic syndrome (MetS), not least the increased
prevalence of cardiovascular risk factors and the ensuing cardiovascular morbidity [5–9].
Recent studies have suggested that adipokines, such as leptin, adiponectin and resistin, pro-
duced by adipocytes and dysregulated in obesity and MetS, are the linchpins of this metabolic
association and the so called ‘psoriatic march’: a concept of how severe psoriasis can drive car-
diovascular comorbidity [10]. They have been shown to contribute independently to the
adverse cardiovascular outcomes in patients with PsO and can be viewed as biomarkers of obe-
sity-related inflammation and cardiovascular risk [4]. With this is mind, one should consider
adipose tissue as an endocrine organ that has the capabilities, through local and systemic fac-
tors, to induce a low-level inflammatory state. Moreover, specific IL-17-secreting Th17 cells
and IL-22-secreting Th22 cells have been seen to infiltrate the adipose tissue and represent
local mediators of inflammation and insulin resistance, something that is being studied in
more detail. Fig 2 represents this relationship between psoriasis, obesity and metabolic
dysfunction.
Sustained inflammation due to psoriatic disease also leads to loss of muscle mass and mus-
cle weakness termed sarcopenia; however, the reasons for these muscle changes in the context
PLOS ONE Psoriatic disease and body composition
PLOS ONE | https://doi.org/10.1371/journal.pone.0237598 August 13, 2020 2 / 22
of inflammation are multifactorial and difficult to define. External factors, such as aging,
decreased physical activity secondary to stiffness and pain, hormonal changes and distur-
bances in protein metabolism are likely to exert considerable influence on this process [11].
Fig 1. Immunopathogenesis of psoriasis. Cell subsets and cytokine signaling pathways implicated in the pathogenesis of psoriasis. Damage to the epidermis
triggers release of antimicrobial peptides including LL-37, which complexes with self-DNA released from cellular membrane rupture. DNA-LL-37 complexes
are autoantigens of psoriasis, which are taken up by dendritic cells, resulting in IL-12 and IL-23 production. The IL-23/Th17 axis actuates a feedforward loop
that favors keratinocyte proliferation, ultimately forming a psoriatic plaque. bFGF: basic fibroblast growth factor; DDC: dermal dendritic cell; GFs: growth
factors; pDC: plasmacytoid dendritic cell; VEGF: vascular endothelial growth factor.
https://doi.org/10.1371/journal.pone.0237598.g001
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Despite this knowledge about the associations between psoriatic disease, adipogenesis and
metabolic dysfunction, there is less emphasis on body mass alterations and distribution
between separate internal compartments: fat-free tissue (lean body mass), extracellular water
and adipose tissue. Body composition, a measure of lean and fat mass proportions, provides a
useful indicator of metabolic health [12], and its measurement in psoriatic disease could pro-
vide a useful insight into cardiometabolic risk, something that could well influence patient
management.
Fig 2. Psoriatic disease and systemic inflammation. The ‘psoriatic march’: it portrays the causal link between psoriasis as a systemic inflammatory
phenomenon and cardiovascular disease. Obesity, a known risk factor for psoriasis, is capable of inducing a low-grade systemic inflammatory state.
Continuous effective systemic therapy may halt the ‘psoriatic march’ through interference with insulin resistance and endothelial dysfunction.
https://doi.org/10.1371/journal.pone.0237598.g002
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Our principal aim was to determine the evidence for the association between psoriasis and
abnormal patterns of fat (including preponderance of visceral fat content) and muscle distri-
bution. We also explored and compared different modalities used for assessment of fat distri-
bution. We hope that this analysis may guide future clinical decision making with respect to
risk assessment, screening and management of psoriatic patients in day-to-day practice,
encouraging more individualized care and leading to better patient outcomes.
Methods
This systematic review was performed following methodology recommended by the Cochrane
Collaboration and is reported according to the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) guidelines [13, 14].
Eligibility criteria
The following inclusion and exclusion criteria were applied.
Inclusion criteria:
Types of studies
• Publication date 2004 –present (inclusive)
• Studies from any geographical location
• English language
• Published studies (including conference papers)
• Grey literature (not published in a peer-reviewed journal) including dissertations/theses
• Any quantitative study (RCT, non-RCT, observational, cohort, case control)
• Studies using qualitative methods of analysis (to describe patterns or themes raised by stud-
ies) seeking to understand body composition phenotypes of psoriatic disease. This includes
original qualitative studies, studies involving secondary analysis of data, and a qualitative
study as part of a mixed methods study e.g. the study also has a quantitative component
• The reference lists of the final articles included for full data extraction were hand searched
for further relevant articles
Types of participants
• Adults (>18 years)
• Diagnosed with psoriasis, psoriatic disease or psoriatic arthropathy/arthritis
• Being treated in any ‘usual care’ setting: primary; secondary; tertiary care, e.g. in the hospital,
hospice, community, home or rehabilitation
• Receiving care typical for that geographical location
Types of outcome measures
• Understanding and learning about body composition and metabolic phenotypes including
measures of body fat and lean mass in men and women with psoriatic disease
• To explore the metabolic, anthropometric and biochemical indices of psoriatic disease
Exclusion criteria:
• Non-English language
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• Published pre-2004
• Any study where quantitative or qualitative data are not analyzed i.e. uninterpreted data;
case reports; any editorial, meta-analysis or review (systematic, narrative, qualitative)
• Treatment guidelines and pathways
• Commentary articles, written to convey opinion or stimulate research/discussion, with no
research component
Types of participants
• Children or Young adults (<18 years)
• Diagnosis of Spondyloarthritis or Spondyloarthropathy, Ankylosing Spondylitis, other
immune-mediated inflammatory diseases; studies that do not focus on psoriatic disease per
se
Types of outcome measures
• Anything that is not concerned with demonstrating either a metabolic, structural or func-
tional relationship to psoriatic disease; studies focusing on individual components of meta-
bolic syndrome (diabetes mellitus, hypertension, hyperlipidemia or fatty liver disease) and
any association with psoriatic disease
Databases and searches
The search strategy was developed by two of the authors (TB and NG) and a librarian. Data-
base searches were performed in PubMed, Medline (Ovid1), Embase (Ovid1), Cochrane
Central Register of Controlled Trials (CENTRAL) and Google Scholar for reports published
between 2004 to November 2019 using a sensitive methodologic filter for studies. A fifteen-
year time frame was chosen to capture the most contemporary and innovative studies in this
area. Search terms and criteria are shown in Table 1. Search results were combined into a sin-
gle Endnote file and duplicates removed.
Table 1. Search terms.
Psoriatic disease
psoriatic arthritis.mp. or exp Arthritis, Psoriatic/
psoriatic arthropathy.mp. or exp Arthritis, Psoriatic/
exp Psoriasis/ or psoriatic disease.mp.
exp Spondylarthritis/ or Spondyloarthropathies/ or spondyloarthritis.mp.
Metabolic composition
metabolic syndrome.mp. or exp Metabolic Syndrome/
exp Body Weight/ or metabolic syndrome.mp. or exp Blood Glucose/ or exp Obesity/ or exp Lipids/ or exp Insulin/
or exp Metabolic Syndrome/ or exp Glucose Tolerance Test/
body composition.mp. or exp Body Composition/
exp Exercise/ or sarcopenia.mp. or exp Muscle, Skeletal/ or exp SARCOPENIA/ or exp Muscular Atrophy/ or exp
Muscle Proteins/
sarcopaenia.mp.
Limits
English language
Humans
Last 15 years of publication
https://doi.org/10.1371/journal.pone.0237598.t001
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Study selection
Two authors (TB, NG) independently reviewed all titles/abstracts in the web-based software
platform Covidence [15] and selected articles for full-text review. Discrepancies were resolved
by consensus.
Data extraction and quality assessment
The data extraction tool was designed by TB and included a Quality Assessment incorporating
a Critical Appraisal Skills Programme (CASP) checklist [16] specific for the study design. The
checklists included criteria for information and selection bias addressing the following
domains: participants, controls, measurement of variables, statistical power, confounding fac-
tors and applicability of results. All included studies were appraised with the Risk Of Bias In
Non-randomized Studies of Interventions assessment tool (ROBINS-I) [17].
Results
Search results
The initial search yielded 5304 titles. After removing duplicates, 1848 titles and abstracts were
screened, then 238 retained for full text review. A further 213 studies were excluded due to:
incorrect outcomes (197), incorrect study design (9), duplicate material (3), incorrect interven-
tion (3) and non-English language (1). A total of 25 studies from 25 publications met the inclu-
sion criteria (Fig 3) with differing methodology: 1 randomized control trial, 1 case-control
study, 19 cross-sectional and 4 prospective cohorts. A search of the grey literature (the first 100
articles sorted by relevance on Google Scholar) retrieved no additional studies. A summary of
the included studies is shown in Table 2.
Population sampled
Twenty-five studies represented a population of 2468 psoriatic patients from 10 countries: Bel-
gium, Brazil, Denmark, France, Italy, Poland, Portugal, Spain, Turkey and UK. Demographics
are shown in Table 3. Studies did not differentiate outcomes according to subtypes of psoriatic
disease; however, five of the studies focused purely on psoriatic arthritis [18–22]. Only four
studies [21–24] reported on the racial and ethnic groups of participants. A control group was
assessed in 10 studies [18, 20, 21, 23, 25–30], and this information was missing in another
study [19]. None of the studies reported on socio-economic status, including employment or
educational attainment of subjects.
Clinical anthropometric assessment
All studies included clinical anthropometric data to varying degrees for overall measurement
of participant shape and size. In all but one study [19], participants’ weight, height and BMI
were measured. Several studies measured waist-to-hip ratio [29, 31–33], and one study supple-
mented this with skinfold thickness and abdominal circumference [31]. Only two studies com-
mented on the attire of recruited subjects and attempted to reduce confounding through
clothing by stipulating a dress code of light clothes and no shoes [24, 34]. These groups were
assessed by a standard operator in a consistent manner. Very few studies incorporated partici-
pant information on smoking, alcohol, nutrition or physical activity, all of which are known to
influence human metabolism [21, 24, 29, 34].
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Fig 3. PRISMA flowchart.
https://doi.org/10.1371/journal.pone.0237598.g003
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Body composition
In general, 24 studies confirmed discrete biologic and body composition changes in patients
with psoriatic disease, which correlated positively with other indicators of metabolic syn-
drome, including waist circumference, waist-to-hip ratio, weight, BMI, plasma concentrations
of low-density lipoprotein (LDL)-cholesterol, leptin and apolipoprotein-B (apo-B).
One study failed to reveal statistically significant differences between psoriatic patients and
controls with respect to maximal aerobic capacity, resting metabolic rate, pulmonary function
Table 2. Meta-summary of included studies.
Author, year and country Study design No. participants
Psoriasis
Controls
Outcomes
Aguiar et al., 2014, Portugal Cross-sectional 60 60 MMI: muscle mass/height2 using Lee’s equation
Akyildiz et al., 2014, Turkey Cross-sectional 31 32 EFT: β = Standardized regression coefficient
Andreevskaia et al., 2013,
Belgium
Cross-sectional 117 0 Body fat (%) using a new computerized conversational system
Balci et al., 2010, Turkey Cross-sectional 46 46 VFA: cm2, VFA/SFA ratio
Balci et al., 2014, Turkey Cross-sectional 38 38 EFA: cm2
Barone et al., 2018, Italy Cross-sectional 168 0 MMI by BIA
Barrea et al., 2015, Italy Cross-sectional 62 62 FM from BIA: %
Barrea et al., 2016, Italy Cross-sectional 180 180 Data on phase angle (PhA), a direct measure by BIA: PhA (˚)
De La Brassinne et al., 2016,
Belgium
Cross-sectional 552 0 Mean body fat percentage (%) using an automatic conversational system
Demirel et al., 2013, Turkey Cross-sectional 30 30 Body composition (%) established with BIA
Diniz Mdos et al., 2016, Brazil Cross-sectional 42 41 Percentage of total fat by DXA: (%)
Engin et al., 2014, Turkey Case-control 242 110 Body composition values (%) measured using the Tanita SC-330 Body Composition
Analyzer1
Ferguson et al., 2019, UK Prospective cohort 60 0 Visceral, subcutaneous, and liver fat percentage on MRI
Galluzzo et al., 2017, Italy Cross-sectional 164 0 Body composition (single-frequency 50 kHz) by BIA
Galluzzo et al., 2018, Italy Prospective cohort 53 0 Body composition (%) by BIA
Ganguly et al., 2016, India Cross-sectional 40 42 LAP index, a measure of visceral fat
Gonul et al., 2017, Turkey Cross-sectional 41 41 Body fat distribution, particularly visceral adipose tissue by ultrasonography: abdominal
fat index (AFI = Pmax/Smin ratio)
Kofoed et al., 2012, Denmark Cross-sectional 9 0 Lean body mass and fat mass (kg) by DXA
Krajewska-Wlodarczyk et al.,
2017, Poland
Cross-sectional 51 44 Total fat mass (kg) Appendicular Lean Mass index (kg/m2) using BIA Skeletal Muscle
Index (%) using BIA
Leite et al., 2018, Brazil Randomised control
trial
97 NR Body fat mass (%) by DXA
Renzo et al., 2011, Italy Prospective cohort 40 0 Fat mass (kg and %) by DXA
Romani, Caixas et al., 2012,
Spain
Cross-sectional 50 50 Body fat (%) using BIA
Romani, Caixas, Ceperuelo et al.,
2012, Spain
Cross-sectional 50 50 Body fat content as calculated by BIA
Tournadre et al., 2017, France Cross-sectional 148 0 Total lean mass (kg), SMI, (kg/m2), Total fat mass (kg), FMI, Overfat (Body fat percentage
>27% for men and 38% for women) by DXA
Toussirot et al., 2019, France Prospective cohort 52 PsO 52
PsA
52 Lean mass, fat mass and fat distribution (android/gynoid regions and visceral fat) by DXA
AFI: abdominal fat index; ALM: appendicular lean mass; BIA: bioelectric impedance analysis; CT: computed tomography; DXA: dual energy X-ray absorptiometry;
EFA: epicardial fat area; EFT: epicardial fat thickness; FM: fat mass; FMI: fat muscle index; LAP: lipid accumulation product; MMI: mean muscle index; MRI: magnetic
resonance imaging; NR = not recorded; SMI: skeletal muscle index; SFA: subcutaneous fat area; VFA: visceral fat area.
https://doi.org/10.1371/journal.pone.0237598.t002
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Table 3. Demographic data of populations.
Author, year and
country
Age of Psoriasis group,
years (mean ± SD unless
stated)
Sex,
female %
Ethnicity Duration, years
(mean ± SD unless
stated)
Disease
type
Participant selection
Aguiar et al., 2014,
Portugal
45.5 ± 13.4 51.7 Caucasian 10.9 ± 11.6 PsA PsA according to CASPAR criteria. Controls recruited
from primary healthcare.
Akyildiz et al., 2014,
Turkey
42.0 ± 11.1 54.8 ND 17.1 ± 10.5 PsO Subjects attending the outpatient dermatology clinic.
Clinical examination in keeping with psoriasis.
Andreevskaia et al.,
2013, Belgium
48.8 ± 14.9 49.5 ND ND PsO Subjects attending a new outpatient psoriasis center
recruited at random of their consultation.
Balci et al., 2010,
Turkey
39.5 ± 14.2 37.0 ND 11.0 ± 8.3 PsO Patients attending outpatient dermatology clinic.
Controls age and sex matched.
Balci et al., 2014,
Turkey
42.2 ± 15.0 31.6 ND 14.9 ± 9.5 PsO Patients attending outpatient dermatology clinic.
Controls age and sex matched.
Barone et al., 2018,
Italy
55.3 ± 9.1 84.2 Caucasian 11.1 ± 8.1 PsA Patients with a clinical diagnosis of RA, SA, and PsA
enrolled
Barrea et al., 2015,
Italy
50.2 ± 10.5 30.0 ND ND PsO Patients with a diagnosis of mild-to-severe psoriasis
lasting for at least 6 months were enrolled, while patients
with pustular, erythrodermic or arthropathic psoriasis or
receiving any systemic treatment for psoriasis including
acitretin, ciclosporin, methotrexate, phototherapy or
biologics for at least 3 months were excluded.
Barrea et al., 2016,
Italy
50.0 (21.0–65.0) 29.0 Caucasian ND PsO Patients attending a university hospital dermatology
clinic. Controls matched based on age, sex and BMI.
De La Brassinne et al.,
2016, Belgium
47.68 ± 16.12 45.7 ND ND PsO Subjects attending a new outpatient psoriasis center
recruited at random of their consultation.
Demirel et al., 2013,
Turkey
37.8 ± 10.6 ND ND ND PsO Patients previously diagnosed with psoriasis by a trained
dermatologist using biopsy. All patients defined as having
mild to moderate psoriasis and receiving only topical
therapy. Moderate psoriasis identified by PASI >10.
Diniz Mdos et al.,
2016, Brazil
47.0 40.5 ND 47.0 PsO Patients with psoriasis and without joint complaints,
adult patients with clinical and/or histopathological
diagnosis of psoriasis, without joint complaints, assisted
at dermatology outpatient clinic. The control group
comprised voluntary patients without psoriasis or any
inflammatory disease, matched by sex and age.
Engin et al., 2014,
Turkey
42.7 50.0 ND 13.6 ± 8.8 PsO University psoriasis clinic. The diagnosis of psoriasis was
based on clinical examination or histopathological
examination in all patients.
Ferguson et al., 2019,
UK
55.0 (43, 62 IQR) 63.0 ND 8.0 (2, 12.2 IQR) PsA Prospective, open label study of adults receiving
apremilast as part of routine care for PsA and/or
psoriasis.
Galluzzo et al., 2017,
Italy
48.6 ± 16.5 36.6 ND ND PsO Chronic plaque psoriasis patients, naive to biological
drugs, treated with ustekinumab in the University
dermatology clinic.
Galluzzo et al., 2018,
Italy
32.1 ± 13.6 24.5 Caucasian 17.1 ± 11.5 PsO Chronic plaque psoriasis patients, naive to biological
drugs, treated with ustekinumab in the University
dermatology clinic.
Ganguly et al., 2016,
India
44.8 ± 12.8 ND ND 0–20 PsO Patients with chronic plaque psoriasis attending the
dermatology outpatient clinic. Healthy controls who
came for a routine health check to our hospital were
included in the study.
Gonul et al., 2017,
Turkey
43.2 ± 15.6 46.3 ND 14.6 ± 12.1 PsO Patients with clinically and histopathologically diagnosed
psoriasis, patients had been receiving systemic or topical
treatment for the last month. Controls recruited from
among patients with warts, tinea pedis, or melanocytic
nevi without any inflammatory disease, and matched for
age, sex and BMI.
(Continued)
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tests, body fatness, body fat distributions and quality of life [31]. Moreover, not all studies
found that these changes were correlated to either skin or joint disease activity [11, 19, 35, 36].
Three studies focused on muscle mass and reported levels of sarcopenia [18, 21, 22]. Aguiar
et al. evaluated muscle mass by way of a muscle mass index (MMI: muscle/height2) and dem-
onstrated reductions for spondyloarthritis with no significant variation between psoriatic
arthritis and ankylosing spondylitis patients. They identified a significant difference in mean
MMI between patients and controls (61.7% vs 43.3%: 7.65 ± 0.98 vs 8.25 ± 0.92; p = 0.001,
OR = 5.23). MMI showed correlation with disease activity indices (BASDAI and BASMI) in
the male AS patients only. However, their findings were not correlated with disease duration,
function or radiological indices. A more recent study assessed sarcopenia and presarcopenia
on the basis of European Working Group On Sarcopenia in Older People (EWGSOP) criteria
and by using defined MMI cut-offs, and identified sarcopenia in 20.0% and presarcopenia in
25.7% of PsA patients. Their assessment did not include a sex- and age-matched control popu-
lation [21].
Measurement techniques
Ten techniques were used to describe body composition: BIA 10, DXA 6, CT 2, ultrasonogra-
phy 1, transthoracic echocardiography 1 and other techniques 5 (including novel automated
Table 3. (Continued)
Author, year and
country
Age of Psoriasis group,
years (mean ± SD unless
stated)
Sex,
female %
Ethnicity Duration, years
(mean ± SD unless
stated)
Disease
type
Participant selection
Kofoed et al., 2012,
Denmark
33.0 ± 8.6 ND ND 15.9 ± 4.4 PsO Eligible participants were anti-TNF–naïve patients with
psoriasis recalcitrant to other systemic treatments and
UV-B therapy. They also had a PASI or DLQI of >10.
Krajewska-
Wlodarczyk et al.,
2017, Poland
65.6 ± 5.9 100 ND PsA 11.1 ± 8.9 PsA/PsO Women diagnosed with PsA, treated at the rheumatology
or dermatology clinic of the municipal hospital. The
diagnosis of PsA was determined based on the CASPAR
criteria. At least 12 months had passed since the last
menstrual period.
PsO 22.9 ± 12.9
Leite et al., 2018,
Brazil
ND ND ND ND PsA ND
Renzo et al., 2011,
Italy
PsA 42.2 ± 8.9 ND ND PsA 14.1 ± 11.2 PsA/PsO Patients divided into two groups: 20 patients with PsO
and 20 with PsA. Twelve patients received infliximab and
28 received etanercept.
PsO 36.8 ± 8.4 PsO 15.0 ± 9.3
Romani, Caixas et al.,
2012, Spain
46.4 ± 17.3 61.3 ND ND PsO PASI� 10 evaluated by the same dermatologist. No
systemic anti-psoriatic therapy (acitretin, ciclosporin,
methotrexate or biologics), natural or artificial UV
sources during the month prior to inclusion.
Romani, Caixas,
Ceperuelo et al., 2012,
Spain
ND ND ND ND PsO Patients eligible for narrow-band UVB phototherapy
recruited excluding the months of high solar irradiance.
Controls without psoriasis matched to the patients’
characteristics. Patients with PsA were excluded, along
with patients and controls with a list of chronic
inflammatory diseases.
Tournadre et al.,
2017, France
54.6 ± 11.0 63 ND 5.5 ± 6.8 PsA ND
Toussirot et al., 2019,
France
PsA 52.5 ± 11.7 51.2 ND PsA 9.1 ± 6.7 PsA/PsO Patients with PsO (plaque psoriasis) or PsA (CASPAR
criteria) were evaluated. Each patient was paired to a
control subject, recruited in the same outpatient
population, and matched for sex, age and BMI.
PsO 50.5 ± 12.8 26.9 PsA 18.1 ± 13.8
ND: not defined.
https://doi.org/10.1371/journal.pone.0237598.t003
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systems for measurement). Body composition outcomes by modality are shown in Table 4.
Four studies [23, 24, 27, 34] measured Phase Angle (PhA), a direct measure of BIA, which
researchers found was lower in the psoriatic patients. Barrea et al. [24] discovered that PhA
was inversely associated with disease severity measured by Psoriasis Area Severity Index
(PASI) and Dermatology Life Quality Index (DLQI); this was also found to be independent of
BMI (P< 0.001), although this study included a low number of subjects.
The following devices were used to derive body composition data for analysis in the 10
included BIA studies: BIA 101, Akern srl, Pontassieve, Florence, Italy [21]; single-frequency 50
kHz BIA 101 RJL, Akern Bioresearch, Florence [23, 24, 27, 34]; Bodystat 1500, Bodystat Ltd.,
Douglas, Isle of Man, UK [31]; Tanita SC-330 Body Composition Analyzer, Tanita Corp.,
Tokyo, Japan [37]; InBody 170, Biospace, South Korea [11]; Tanita TBF300, Tanita Corpora-
tion, Tokyo, Japan [35, 36].
All studies bar one [31] demonstrated less favorable body composition data in psoriasis
patients compared to controls.
Body composition associations
Balci et al. [32] identified increased visceral fat area (VFA) using CT in psoriasis patients vs.
controls. Multiple linear regression analysis in all study subjects indicated that VFA was signif-
icantly associated with waist:hip ratio, age, body weight and presence of metabolic syndrome,
though not PASI score, duration or type of disease, smoking habit and therapies. A second
study from this group studied epicardial fat [33], in which epicardial fat area (EFA) and coro-
nary artery calcium scoring (CACS) were measured in patients with psoriasis and controls:
EFA was significantly associated with CACS, waist circumference and age in the psoriasis
patients only. No clinical features or laboratory findings were coupled to EFA. Barone et al.
[21] showed age, CRP and disability were associated with sarcopenia, whereas the type of rheu-
matic disease (RA, PsA or AS), gender, calorie and protein intake, physical activity level, bio-
logic treatment, duration of disease and ESR were not associated with an increased risk of
sarcopenia.
Effect of treatments
Six studies reported on cardiometabolic and body composition improvements on patient pro-
files after receiving specific interventions: hypocaloric diet with omega-3 supplementation
[19], phosphodiesterase-4 (PDE4) inhibition with apremilast [20], narrowband ultraviolet
(NB-UVB) therapy [35], anti-TNFα administration with infliximab or etanercept [29], anti-
TNFα administration with infliximab or adalimumab [28] and anti-IL-12/23 administration
with ustekinumab [23].
Assessment of bias
The risk of bias quality assessment of included studies is presented in Table 5. Six of the stud-
ies, whilst identifying as case-control, were reassigned as cross-sectional design on account of
their methodology [22, 24, 36, 38–40]. Nine studies did not include a control group [18, 20, 21,
23, 25–29]. Several studies did not fully specify how their participants were recruited [21, 26,
29, 31] and there was uncertainty about this information from an additional four studies [11,
18, 20, 28]. The sample size was small (< 40) for a number of studies [28, 31, 33, 38]. Overall,
four studies were regarded to be at high risk of bias [18, 21, 26, 29], two at medium risk of bias
[28, 31] and 19 at low risk of bias [11, 19, 20, 22–25, 27, 30, 32–41] using the ROBINS-I tool.
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Table 4. Body composition outcomes by modality.
Study Results PsO vs
HC
Bioimpedance analysis (BIA) Barone et al., 2018 The prevalence of sarcopenia was about 20% in all the three rheumatic diseases, whereas
presarcopenia was significantly different in RA, PsA and AS (P = 0.006).
+
Barrea et al., 2015 PASI score was significantly associated with the % FM and CRP levels. At multiple
regression analysis, the major predictor of PASI score were FM among BIA parameters,
(r2 = 0.537, β = 0.740, P < 0.001.
+
Barrea et al., 2016 PhAs� 4.8˚ and� 4.9˚ identified psoriatic patients who had the highest clinical
severity and the lowest quality of life, respectively. Psoriatic patients presented small
PhAs, with a novel association with clinical severity, quality of life and MetS. Among
psoriatic patients, the PhA was the major index value for the diagnosis of MetS (OR
5.87, 95% CI 5.07–6.79) and was inversely associated with both PASI and DLQI,
independently of BMI (P< 0.001).
+
Demirel et al., 2013 Maximal aerobic capacity, resting metabolic rate, pulmonary function tests, body
fatness, body fat distributions and quality of life were not statistically different between
patients with psoriasis and controls in males and females.
ND
Engin et al., 2014 Statistically significant differences were recorded in terms of weight (kg), body fat
percentage, fat mass (kg), TBW percentage, metabolic age, visceral fat rating, BMI and
degree of obesity among treated and untreated patients and control subjects.
+
Galluzzo et al., 2017 Compared to men, women had several significantly higher bioelectrical impedance
parameters including reactance, fat mass% and adipose tissue%. The values of adipose
tissue were positively correlated only with patients’ age (p ¼ .021) and age at disease
onset (p ¼ .0006) but not with disease severity. In addition, the use of BMI cut-offs
allowed to categorize 36.7% of women and 19.2% of men as obese, while fat mass%
showed that 53.3% of women and 48.1% of men were obese.
+
Galluzzo et al., 2018 At baseline, psoriatic patients showed a lower BCM and mean PhA score. During
ustekinumab treatment, the mean PhA and BCM scores increased with an improvement
in psoriatic disease.
+
Krajewska-Wlodarczyk
et al., 2017
Sarcopenia, using ALM index and SMI, was diagnosed in 13.7% and 43.1% of PsA
women, and in healthy women in 9% and 20.4%, respectively. In the group of PsA,
sarcopenia was associated with a significant increase in the occurrence of disorders of
bone mineralization (72.7% vs. 41.3% in patients without a decrease in muscle mass).
There was no correlation between the loss of muscle mass, bone density, and activity of
PsA.
+
Romani, Caixas et al.,
2012
With an identical body mass index, psoriatic patients showed a higher body fat content
as calculated by electric bioimpedance, which correlated positively with waist
circumference, and higher plasma concentrations of LDL-cholesterol, leptin and apo-B.
+
Romani, Caixas,
Ceperuelo et al., 2012
Ferritin, B12 and CRP decreased significantly after NB-UVB therapy. Vitamin D levels
reached adequate levels after phototherapy; however, no relationship with PASI
improvement was observed.
+
Dual energy X-ray absorptiometry
(DXA)
Diniz Mdos et al., 2016 Dual energy X-ray absorptiometry was more capable of identifying obesity compared
with BMI and WC both in psoriatic and control patients.
+
Kofoed et al., 2012 Truncal fat percentage was negatively correlated with insulin sensitivity (r = −0.78;
P = 0.01) and positively correlated with plasma leptin (r = 0.88; P = 0.002). After 12
weeks of therapy (infliximab = 5, adalimumab = 4), there were no significant changes in
insulin sensitivity, fasting glucose, hemoglobin A1c, or C-peptide. Body fat increased by
6.5% and truncal fat increased by 11.4%. Leptin concentrations significantly decreased
after anti-TNF treatment.
+
Leite et al., 2018 The group on a hypocaloric diet + omega-3 supplementation (3 g/day) had significant
weight loss (-1.79 ± 2.4; P = 0.004), as well as waist circumference (-3.28 ± 3.5; P = 0.001
and body fat (-1.2 ± 2.2; P = 0.006) reduction. There was no significant correlation
between weight loss and disease activity improvement.
+
Renzo et al., 2011 In both groups, a significant percentage change of body weight, fat, and lean mass,
compared to baseline (PsO: body weight +3.8 ± 2.5%, fat mass 8.6 ± 10.5%, lean mass
1.9 ± 2.4%; PsA: body weight +3.7 ± 3.4%, fat mass 8.9 ± 17.3%, lean mass 2.9 ± 3.4%)
was observed.
+
Tournadre et al., 2017 Sarcopenia with a decrease in muscle mass and function was observed in 5 RA (7.8%), 1
SpA (1.7%) and 1 PsA (9.1%). Sarcopenia in terms of reduced SMI only (1) was not
more frequent occurring in 5 RA (7.8%), 3 SpA (5.1%) and 1 PsA (9.1%).
+
(Continued)
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Additional analyses
Sensitivity analysis was not feasible due to clinical heterogeneity preventing meta-analysis.
Discussion
To our knowledge, this is the first systematic review examining the relationship between psori-
atic disease and whole-body composition as a distinct entity from metabolic syndrome.
Table 4. (Continued)
Study Results PsO vs
HC
Toussirot et al., 2019 Total fat mass was increased in PsO but not in PsA. Android fat and visceral fat were
found higher in PsO (p< 0.05), while the fat mass measurements did not differ between
the patients with PsA and controls. WC was higher in patients with PsO compared to
their controls. Leptin, leptin/fat mass ratio, and total adiponectin were elevated in PsA.
Insulin levels and HOMA were increased in both PsO and PsA groups. In patients with
PsO, android and visceral fat were correlated with SCORE (r = 0.3; P = 0.02 and r = 0.6;
P< 0.0001 respectively).
+
Ultrasonography Gonul et al., 2017 AFI was not associated with psoriasis in subjects with metabolic syndrome (P = 0.495)
or with Psoriasis Area and Severity Index (r = 0.123; P = 0.443).
+
Transthoracic echocardiography Akyildiz et al., 2014 EFT was significantly associated with MS (P< 0.01), age (P< 0.05) and female gender
(P< 0.05) in psoriasis patients only.
+
Computed tomography (CT) Balci et al., 2010 The mean VFA value and VFA/SFA ratio of the psoriasis patients were significantly
higher compared with control patients (123.4 ± 80.3 vs. 81.2 ± 59.8 cm2 and
0.734 ± 0.593 vs. 0.491 ± 0.336; P = 0.005 and P = 0.017, respectively). Fasting blood
sugar levels were significantly higher in psoriasis patients, compared with control
patients (101.8 ± 43.5 vs. 83.4 ± 9.1 mg/dl; P = 0.005). Multiple linear regression analysis
indicated that waist-to-hip ratio, age, body weight, the presence of psoriasis and
metabolic syndrome were significantly associated with VFA.
+
Balci et al, 2014 Mean EFA in patients with psoriasis was significantly higher than in controls (13.8 ± 8.4
vs. 97 ± 6.4 cm2, respectively; P = 0.02), but mean CACS did not differ significantly
between the two groups (55.2 ± 65.4 vs. 27.8 ± 29.3; P > 0.05).
+
Other Aguiar et al., 2014 62% of patients had sarcopenia and there was a significant difference in MMI between
patients and controls (7.65 ± 0.98 vs 8.25 ± 0.92; P = 0.001, OR = 5.23). In male patients,
there was a statistically significant moderate negative correlation between MMI and
BASDAI and BASFI (P = -0.536 and P = -0.445). No other significant correlations were
identified.
+
Mean muscle index (MMI)
Body fat (%) Andreevskaia et al., 2013 Mean body fat percentage 31.84 + 8.58% (36.60 + 7.32% in women and 27.17 + 7.13% in
men) exceeding the maximum of a normal population by a mean absolute percentage of
3.74% (corrected = 13.30%).
+
Body fat percentage (%) De La Brassinne et al.,
2016
These results confirm the increased frequency of obesity in patients with psoriasis and
are obtained by a fully automated conversational system usable by the patient.
+
Lipid accumulation product (LAP)
index, a measure of visceral fat
Ganguly et al., 2016 A statistically significant difference (P< 0.001) was observed between the LAP index of
controls (23.79 ± 13.02) and that of psoriasis patients (46.42 ± 27.2). LAP index was
significantly higher (P = 0.028) in the moderate-to-severe psoriasis group
(56.02 ± 30.09) as compared to the mild psoriasis group (36.82 ± 20.49).
+
MRI of abdominal fat distribution Ferguson et al., 2019 Mean weight loss after 3 and 6 months apremilast treatment was -1.4kg (95% CI -2.1,
-0.6, P = 0.001) and -2.2kg (95% CI -3.1, -1.4, P < 0.001), respectively.>5% weight loss
was achieved in 6.1% (3/49) and 21.4% (9/42) after 3 and 6 months of treatment,
respectively.
+
P-values are reported when provided in the published studies; +: favors controls.
AFI: abdominal fat index; ALM: appendicular lean mass; AS: ankylosing spondylitis; BCM: body cellular mass; BIA: bioelectric impedance analysis; BMI: body mass
index; CACS: coronary artery calcium score; CT: computed tomography; DXA: dual energy X-ray absorptiometry; EFA: epicardial fat area; EFT: epicardial fat thickness;
FM: fat mass; FMI: fat muscle index; HC: healthy controls; HOMA: Homeostatic Model Assessment; LAP: lipid accumulation product; MetS: metabolic syndrome;
MMI: mean muscle index; MRI: magnetic resonance imaging; ND: no difference; NR = not recorded; PhA: data on phase angle; PsA: psoriatic arthritis; PsO: psoriasis;
RA: rheumatoid arthritis; SCORE: Systematic Coronary Risk Evaluation; SMI: skeletal muscle index; SFA: subcutaneous fat area; SpA: spondyloarthritis; TBW: total
body water; VFA: visceral fat area; WC: waist circumference.
https://doi.org/10.1371/journal.pone.0237598.t004
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Table 5. Risk of bias assessment.
Was the sample
representative of
the target
population?
Were cases
recruited in
an
acceptable
way?
Did the
study
include a
control
group?
Were the
controls
selected in
an
acceptable
way?
Was there
matching
of
controls?
Was the sample
size based on pre-
study
considerations of
statistical power?
Were the
groups
treated
equally?
Was there
appropriate
statistical
analysis?
Were
important
confounding
factors
identified and
accounted for?
Will the
results
help
locally?
Aguiar et al.,
2014
Y Y Y Y N N Y Y Y Y
Akyildiz et al.,
2014
Y Y Y Y N N Y Y Y Y
Andreevskaia
et al., 2013
Y Y N N/A N/A N N/A N ? Y
Balci et al.,
2010
Y Y Y Y Y Y Y Y ? Y
Balci et al.,
2014
Y Y Y Y Y Y Y Y ? Y
Barone et al.,
2018
N N N N/A N/A N N/A N N N
Barrea et al.,
2015
Y Y Y Y Y N Y Y Y Y
Barrea et al.,
2016
Y Y Y Y Y Y Y Y Y Y
De La
Brassinne
et al., 2016
? N N N/A N/A N N/A Y N N
Demirel et al.,
2013
? N Y ? N N ? Y N Y
Diniz Mdos
et al., 2016
Y ? Y Y Y N Y Y N Y
Engin et al.,
2014
Y Y Y ? N Y Y Y Y Y
Ferguson et al.,
2019
Y ? N N/A N/A N N/A Y ? Y
Galluzzo et al.,
2017
Y Y N N/A N/A N N/A Y Y Y
Galluzzo et al.,
2018
? Y N N/A N/A N N/A Y Y Y
Ganguly et al.,
2016
Y Y Y Y N Y Y Y N Y
Gonul et al.,
2017
? Y Y Y Y N Y Y N Y
Kofoed et al.,
2012
? ? N N/A N/A N N/A Y N N
Krajewska-
Wlodarczyk
et al., 2017
Y ? Y ? Y N ? Y Y Y
Leite et al.,
2018
Y Y Y ? ? N Y Y Y N
Renzo et al.,
2011
N N N N/A N/A N N/A N N N
Romani,
Caixas et al.,
2012
Y Y Y Y Y N Y Y Y Y
(Continued)
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Strengths of the review include use of a high degree of rigor in its search strategy and screening
procedures and using relevant standards for performing systematic reviews. We tried to reflect
the complete picture of both published and unpublished literature on this topic including
smaller studies and conference proceedings. Evidently, the last decade has seen an exciting
expansion of interest in the development and validation of new modalities for the assessment
of body composition. Our study provides evidence for a relationship between certain body
composition phenotypes and the occurrence of psoriasis, including higher overall body fat, vis-
ceral fat and sarcopenia, that is similar, yet distinct, from the metabolic syndrome. Several
aspects of body composition, specifically the amount and distribution of body fat and lean
mass, are now understood to be important health outcomes in adults and should form an
important part of the ongoing clinical assessment of patients with psoriasis. However, the issue
of whether body compartment distribution is a result of severe psoriasis or a causative factor
in its development remains contentious. It is likely that novel systems will eventually supple-
ment less sophisticated bedside measurements and influence key aspects of risk assessment,
prognostication and management.
We found an increased prevalence of body composition derangements in psoriatic patients
compared with controls. As expected, parameters associated with obesity, such as weight, body
fat percentage, fat mass and degree of obesity, were higher in the psoriasis groups than in the
control groups, irrespective of therapy. Such an association between obesity and psoriasis has
been well documented, first described in 1986 [42]. Traditional epidemiologic studies have
focused on weight or BMI to define obesity rather than altered body composition. We found
conflicting data on the association between psoriasis severity, such as PASI, and body compo-
sition parameters, indicating that a causal link is not definitive. Previous studies have alluded
to a dose-response relationship between psoriasis severity and metabolic syndrome [43], sup-
ported by translational studies showing T-helper cell cytokine upregulation in the blood and
skin of psoriasis patients, leading to effects on lipid metabolism and insulin resistance [44].
Furthermore, our data exemplify how there is insufficient evidence to infer that PsA carries a
higher metabolic burden than PsO; thus, more studies are required in this area to distinguish
distinct body composition and metabolic profiles of subtypes of psoriatic disease.
In this review, treatment with anti-IL-12/23 or PDE4 inhibitors was associated with more
favorable body composition profiles than anti-TNFα treatments, findings which mirror previ-
ous observations of increases in BMI seen with this drug class [45, 46]. IL-17, one of the key
Table 5. (Continued)
Was the sample
representative of
the target
population?
Were cases
recruited in
an
acceptable
way?
Did the
study
include a
control
group?
Were the
controls
selected in
an
acceptable
way?
Was there
matching
of
controls?
Was the sample
size based on pre-
study
considerations of
statistical power?
Were the
groups
treated
equally?
Was there
appropriate
statistical
analysis?
Were
important
confounding
factors
identified and
accounted for?
Will the
results
help
locally?
Romani,
Caixas,
Ceperuelo
et al., 2012
Y Y Y Y Y N Y Y Y Y
Tournadre
et al., 2017
? ? N N/A N/A N N/A Y N Y
Toussirot
et al., 2019
Y Y Y Y Y N Y Y Y Y
N: no; N/A: not applicable; Y: yes;?: unclear.
https://doi.org/10.1371/journal.pone.0237598.t005
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proinflammatory cytokines in psoriasis, mechanistically links inflammation with insulin resis-
tance and adipocyte dysfunction [47]. IL-17A producing cells are thought to be pathogenic in
driving inflammation in obesity and progression of obesity-related inflammatory diseases, sug-
gesting that causality between psoriasis and adipogenesis is likely to be bidirectional [48].
From this perspective, there are likely to be therapeutic implications of targeting proinflamma-
tory factors like IL-17 or IL-12/23 in metabolic dysfunction associated with psoriatic disease.
Our review highlights that there are no data comparing and validating body composition
techniques in a psoriatic population; therefore, drawing conclusions about the most precise or
reliable technique is not possible. Due to its non-invasiveness, low cost and portability, it is
easy to appreciate how BIA was adopted by most researchers. The technique relies on the
assumption that the volume of fat-free tissue will be proportional to the electrical conductivity
of the body. It employs a small electric current to measure the resistance and reactance at dif-
ference frequencies against various tissues in the body e.g. lipid has a high resistance to the
flow of current, therefore shows a high impedance reading, whereas muscle, which stores most
of our body water, has lower impedance. BIA assessment tools have been considered a promis-
ing approach for the quantitative measurement of tissue characteristics over time, as well as
demonstrating the direct relativity between fluctuations in body composition and prognosis,
clinical condition and quality of life [49]. The technique offers reliable data on body composi-
tion provided that suitable (i.e. age-, sex- and population-specific) equations for the calculation
of body compartments are applied [50]. However, a major limitation of this technique pertains
to measurement discrepancies between devices from different manufacturers and the lack of
internationally recognized standard reference values.
PhA is thought to be one of the most clinically relevant parameters of BIA. It is defined as
the ratio of resistance (intracellular and extracellular resistance) to reactance (cell membrane-
specific resistance), expressed as an angle. It is considered an indicator of cellular health,
where higher values reflect cell membrane integrity and better cell function. In healthy popula-
tions, increasing age bestows a lower PhA due to a reduction in reactance and a parallel loss of
muscle mass and an increase in resistance due to the declining proportion of body water at the
expense of fat mass. In disease, PhA is often reduced because of infection, inflammation or dis-
ease-specific determinants [51]. Recent studies have reported that PhA in humans follows a
linear relationship with cellular health and can be considered a prognostic tool in certain med-
ical disorders, including cancer, cirrhosis and diabetes mellitus [24, 52–56]. It is important to
note that not all BIA devices can detect phase-sensitive impedance variation that can be used
for assessment of phase angle.
It is clear that there is no single method of body composition measurement that allows for
the delineation of all tissues and organs, and there are pros and cons of all techniques. The
seemingly unsophisticated measurements of skin thickness, BMI and waist circumference can
provide simple longitudinal assessments of fatness and metabolic risk despite their poor accu-
racy and inability to differentiate fat and lean masses. The value of any approach in supporting
clinical practice is enhanced by the availability of reference data. Recent developments include
MRI for fat distribution.
Limitations
This systematic review should be interpreted in the context of the reported studies which were
heterogeneous in several aspects. Firstly, the observational studies recruited different extents
and subtypes of psoriatic disease, some with associated arthritis, and measured different
aspects of body composition, making definitive conclusions problematic. Secondly, there was
poor matching of patients and controls across all studies and little consideration for the
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potential confounding effects of key determinants of metabolism, e.g. physical activity, age and
smoking. Finally, BIA-estimated percentage of body fat varies greatly with population and age
and is directly and closely related to various health outcomes such as cardiovascular diseases.
Despite its prognostic potential, BIA has not been validated in population studies or clinical
practice due to lack of normal population reference limits for comparison and is also influ-
enced by other factors such as age, sex and race [57]. We aimed to present a wide variety of
research endeavors in this upcoming field though we recognize that we may not have captured
smaller conference proceedings or non-English publications.
Further considerations
We suggest that body composition indices should be analyzed in more detail using a broader
range of techniques and imaging systems across the clinical spectrum of psoriatic patients in
order to generate validated methods of assessment, particularly with regards to the prognostic
ability of BIA and PhA. Further studies are needed to address the discrepancies in bioimpe-
dance parameters within body compartments and between different devices and the deviation
from health to disease. We hope that future studies will reveal insights into drug-specific alter-
ations in body composition profiles in psoriatic disease, enabling clinicians to practice more
stratified medicine and treat more effectively the metabolic components of patients’ disease
that are so often neglected in clinical practice and associated with worse outcomes.
Conclusions
In conclusion, this study provides evidence for a relationship between certain body composi-
tion phenotypes and the occurrence of psoriasis, including higher overall body fat, visceral fat
and sarcopenia that are similar, albeit distinct, from the metabolic syndrome. Several aspects
of body composition, specifically the amount and distribution of body fat and lean mass, are
now understood to be important health outcomes in adults and should form an important
part of the ongoing assessment of patients with psoriasis. However, the issue of whether body
compartment distribution is a result of severe psoriasis or a causative factor in its development
remains contentious. It is hoped that novel systems will eventually supplement less sophisti-
cated bedside measurements and influence key aspects of risk assessment, prognostication and
management.
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